Cargando…

Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after pharmacologic provocation) and the response to ACE inhibition

OBJECTIVE: The objective of this study was to evaluate subacute changes in renin–angiotensin–aldosterone system (RAAS) activity during angiotensin-converting enzyme inhibitor (ACEI) therapy in dogs with experimental RAAS activation. METHODS: Analysis of data (urine aldosterone:creatinine ratio (UAld...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ames, Marisa K, Atkins, Clarke E, Lantis, Andrea C, zum Brunnen, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843907/ https://www.ncbi.nlm.nih.gov/pubmed/27009288 http://dx.doi.org/10.1177/1470320316633897

Ejemplares similares

The renin‐angiotensin‐aldosterone system and its suppression
por: Ames, Marisa K., et al.
Publicado: (2019)

Comparison of 24-h Urinary Aldosterone Level and Random Urinary Aldosterone-to-Creatinine Ratio in the Diagnosis of Primary Aldosteronism
por: Wu, Che-Hsiung, et al.
Publicado: (2013)

New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) I: Endogenous Angiotensin Converting Enzyme (ACE) Inhibition
por: Fagyas, Miklós, et al.
Publicado: (2014)

Renal Modulation: The Renin-Angiotensin-Aldosterone System (RAAS)
por: Natarajan, Aruna, et al.
Publicado: (2008)

RAAS-Blockade in COVID-19: The Ace of Spades?
por: Agarwal, Krishna A., et al.
Publicado: (2021)

New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) II: Albumin Suppresses Angiotensin Converting Enzyme (ACE) Activity in Human
por: Fagyas, Miklós, et al.
Publicado: (2014)

RAAS, ACE2 and COVID-19; a mechanistic review
por: Elshafei, Ahmed, et al.
Publicado: (2021)

SUN-LB98 RAAS Triple-A Analysis for the Screening of Primary Aldosteronism
por: Burrello, Jacopo, et al.
Publicado: (2020)

New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) IV: Circulating ACE2 as a Biomarker of Systolic Dysfunction in Human Hypertension and Heart Failure
por: Úri, Katalin, et al.
Publicado: (2014)

New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) III: Endogenous Inhibition of Angiotensin Converting Enzyme (ACE) Provides Protection against Cardiovascular Diseases
por: Fagyas, Miklós, et al.
Publicado: (2014)

Interaction between RAAS inhibitors and ACE2 in the context of COVID-19
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

ACE2, SARS-CoV-2 und RAAS-Blocker
por: Kintscher, Ulrich, et al.
Publicado: (2021)

Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy
por: Ghazi, Lama, et al.
Publicado: (2017)

Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes
por: Gnudi, Luigi, et al.
Publicado: (2010)

Aliskiren, Fosinopril, and Their Outcome on Renin-Angiotensin-Aldosterone System (RAAS) in Rats with Thyroid Dysfunction
por: Farhadi, Susan A. S., et al.
Publicado: (2019)

The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies
por: Hassani, Bahareh, et al.
Publicado: (2023)

Reply to: ‘Interaction between RAAS inhibitors and ACE2 in the context of COVID-19’
por: Zheng, Ying-Ying, et al.
Publicado: (2020)

Why the renin–angiotensin–aldosterone system (RAAS) in critically ill patients can no longer be ignored
por: Zarbock, Alexander, et al.
Publicado: (2021)

SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors
por: Milne, Stephen, et al.
Publicado: (2020)

Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS)
por: Cadegiani, Flavio A., et al.
Publicado: (2020)

Different roles of the RAAS affect bone metabolism in patients with primary aldosteronism, Gitelman syndrome and Bartter syndrome
por: Tang, Wangna, et al.
Publicado: (2022)

An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers
por: Maideen, Naina Mohamed Pakkir, et al.
Publicado: (2022)

Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels
por: Gant, Christina M., et al.
Publicado: (2017)

Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis
por: Pirola, Carlos J., et al.
Publicado: (2020)

Activation of renin–angiotensin–aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats
por: Yuan, Yi-Ming, et al.
Publicado: (2015)

Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin–angiotensin-aldosterone system (RAAS) dysregulation
por: Augustine, Robin, et al.
Publicado: (2022)

The Relationship between Renin–Angiotensin–Aldosterone System (RAAS) Activity, Osteoporosis and Estrogen Deficiency in Type 2 Diabetes
por: Mkhize, Bongeka Cassandra, et al.
Publicado: (2023)

Dysregulation of the Renin-Angiotensin-Aldosterone System (RAA) in Patients Infected with SARS-CoV-2-Possible Clinical Consequences
por: Dettlaff-Pokora, Agnieszka, et al.
Publicado: (2021)

Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease
por: Galizzi, Alberto, et al.
Publicado: (2021)

Prevalence of aldosterone breakthrough in dogs receiving renin‐angiotensin system inhibitors for proteinuric chronic kidney disease
por: Ames, Marisa K., et al.
Publicado: (2022)

Mechanical dependency of the SARS-CoV-2 virus and the renin-angiotensin-aldosterone (RAAS) axis: a possible new threat
por: Sen, Rohit, et al.
Publicado: (2021)

SUN-191 The Creatinine, the Crib and the Manometer - Navigating the Labyrinth of Primary Aldosteronism
por: Hashmi, Hiba, et al.
Publicado: (2020)

RAAS inhibition and mortality in hypertension
por: Ferrari, Roberto
Publicado: (2013)

The RAAS Goodfellas in Cardiovascular System
por: Caputo, Ilaria, et al.
Publicado: (2023)

Urinary Creatinine and Arsenic Metabolism
por: Gamble, Mary V., et al.
Publicado: (2005)

ACE2 as a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System
por: Michaud, Veronique, et al.
Publicado: (2020)

Mitochondrial reactive oxygen species (ROS) as signaling molecules of intracellular pathways triggered by the cardiac renin-angiotensin II-aldosterone system (RAAS)
por: De Giusti, V. C., et al.
Publicado: (2013)

The influence of renin angiotensin aldosterone system (RAAS), endothelial nitric oxide synthase (eNOS) and erythropoietin (EPO) on COVID-19 complications
por: Papadopoulos, Konstantinos I., et al.
Publicado: (2022)

Comparison of Severity of COVID-19 Infection among Patients Using RAAS Inhibitors and Non-RAAS Inhibitors
por: Reddy, Paidi Ramakrishna, et al.
Publicado: (2021)

Antifibrotic Roles of RAAS Blockers: Update
por: Zhang, Ying-Ying, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tjnv1a8eieufv6tl08i2uag214